# GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose

> **NCT03943875** · PHASE4 · COMPLETED · sponsor: **The University of Texas Medical Branch, Galveston** · enrollment: 767 (actual)

## Conditions studied

- Immunization
- Efficacy
- Human Papilloma Virus

## Interventions

- **BIOLOGICAL:** 9-valent HPV vaccine, 2 dose efficacy
- **BIOLOGICAL:** 9-valent HPV vaccine, 3 doses standard timing

## Key facts

- **NCT ID:** NCT03943875
- **Lead sponsor:** The University of Texas Medical Branch, Galveston
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-17
- **Primary completion:** 2025-01-13
- **Final completion:** 2025-01-13
- **Target enrollment:** 767 (ACTUAL)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03943875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03943875, "GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03943875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*